Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance

Histology and Histopathology

Volumn 27, Issue 8, 2012, Pages 1093-1101

  Fernández Martínez, Ana B ^a   Carmena, María J ^a   Isabel Arenas, M ^b   Bajo, Ana M ^a   Prieto, Juan C ^a   Sánchez Chapado, Manuel ^a,c  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Department of Cell Biology and Genetics ^*  (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

COX 2; Prognostic marker; Prostate cancer; VIP; VPAC 1 and VPAC 2 receptors

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; TUMOR MARKER; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADENOCARCINOMA; AGED; ARTICLE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPAIN; SURVIVAL RATE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPAIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84864944353     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Abedinpour P., Baron V.T., Welsh J. and Borgström P. (2011). Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo. Prostate 71, 813-823.
2. Arya M., Bott S.R., Shergill I.S., Ahmed H.U., Williamson M. and Patel H. (2006). The metastatic cascade in prostate cancer. Surg. Oncol. 15, 117-128.
3. Bensalah K., Lotan Y., Karam J.A. and Shariat S.F. (2008) New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 11, 112-120.
4. Castelli T., Cimino S., Magno C. and Morgia G. (2010). Molecular markers for prostatic cancer. Front. Biosci. 2, 641-656.
5. Chang J.T., Chen I.H., Liao C.T., Wang H.M., Hsu Y.M., Hung K.F., Lin C.J., Hsich L.L. and Cheng A.J. (2002). A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin. Biochem. 35, 591-596.
6. Clarke N.W., Hart C.A. and Brown M.D. (2009). Molecular mechanisms of metastasis in prostate cancer. Asian J. Androl. 11, 57-67.
7. Collado B., Gutiérrez-Cañas I., Rodríguez-Henche N., Prieto J.C. and Carmena M.J. (2004). Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul. Peptides 119, 69-75.
8. Collado B., Sánchez-Chapado M., Prieto J. C and Carmena M.J. (2006). Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Mol. Cell. Endocrinol. 249, 116-122.
9. Dandekar D.S. and Lokeshwar B.L. (2004). Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin. Cancer Res. 10, 8037-8047.
10. Evans C.P. (2009) Identification of molecular targets in urologic oncology. World J. Urol. 27, 3-8.
11. Fernández-Martínez A.B., Collado B., Bajo A.M., Sánchez-Chapado M., Prieto J.C. and Carmena M.J. (2007). Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-ÎB in human prostate cell lines. Differential time-dependent responses in cancer progression. Mol. Cell. Endocrinol. 270, 8-16.
12. Fernández-Martínez A.B., Bajo A.M., Sánchez-Chapado M., Prieto J.C. and Carmena M.J. (2009). Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Prostate 69, 774-786.
13. Fernández-Martínez A.B., Bajo A.M., Arenas M.I., Sánchez-Chapado M., Prieto J.C. and Carmena M.J. (2010). Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. Cancer Lett. 299, 11-21.
14. Fritzsche F.R., Jung M., Tölle A, Kristiansen I., Lein M., Johannsen M., Dietel M., Jung K. and Kristiansen G. (2008). ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur. Urol. 54, 1097-1106.
15. Fujita H., Koshida K., Keller E.T., Takahashi Y., Yoshimito T., Namiki M. and Mizokami A. (2002) Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53, 232-240.
16. García-Fernández M.O., Solano R.M., Carmena M.J., Busto R., Bodega G., Ruíz-Villaespesa A., Prieto J.C. and Sánchez-Chapado M. (2003). Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 24, 893-902.
17. Gutiérrez-Cañas I., Rodríguez-Henche N., Bolaños O., Carmena M.J., Prieto J.C. and Juarranz M.G. (2003). VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Br. J. Pharmacol. 139, 1050-1058.
18. Helpap B. and Egevad L. (2009). Modified Gleason grading. An updated review. Histol. Histopathol. 24, 661-666.
19. Howell W.M. and Rose-Zerilli M.J. (2007) Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J. Nutr. 137, 194S-199S.
20. Izawa J.I. and Dinney C.P. (2001). The role of angiogenesis in prostate and other urologic cancers: a review. Can. Med. Assoc. J. 164, 662-670.
21. Jemal A., Siegel R., Xu J. and Ward E. (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300.
22. Juarranz M.G., Bolaños O., Gutiérrez-Cañas I., Lerner E.A., Robberecht P., Carmena M.J., Prieto J.C., Rodríguez-Henche N. (2001). Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell. Signal. 13, 887-894.
23. Khor L.Y., Bae K., Pollack A., Hammond M.E., Grignon D.J., Venkatesan V.M., Rosenthal S.A., Ritter M.A., Sandler H.M., Hanks G.E., Shipley W.U. and Dicker A.P. (2007). COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol. 8, 912-920.
24. Liu X.H., Kirschenbaum A., Yao S., Lee R., Holland J.F. and Levine A.C. (2000). Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 164, 820-825.
25. Lopergolo A. and Zaffaroni N. (2009). Biological markers of outcome prediction in prostate cancer. Cancer 115 (Suppl 13), 3058-3067.
26. Mol A.J., Geldof A.A., Meijer G.A., van der Poel H.G. and van Moorselaar R.J. (2007). New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration. J. Cancer Res. Clin. Oncol. 133, 687-695.
27. Niu Z., Ren G. and Song S. (2008). Diagnosis and treatment for prostate cancer. Chinese German J. Clin. Oncol. 7, 492-494, 2008.
28. Polak J.M. and Bloom S.R. (1984). Localisation and measurement of VIP in the genitourinary system of man and animals. Peptides 5, 225-230.
29. Sánchez-Chapado M., Olmedilla G., Cabeza M., Donat E. and Ruíz A. (2003). Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 54, 238-247.
30. Slater M.D., Lauer C., Gidley-Baird A. and Barden J.A. (2003). Markers for the development of early prostate cancer. J. Pathol. 199, 368-377.
31. Sooriakumaran P., Coley H.M., Fox S.B., Macanas-Pirard P., Lovell D.P., Henderson A., Eden C.G., Miller P.D., Langley S.E., Laing R.W. (2009). A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res. 29, 1483-1488.
32. Sotomayor S., Carmena M.J., Schally A.V., Varga J.L., Sánchez-Chapado M., Prieto J.C. and Bajo A.M. (2007). Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormonereleasing hormone. Int. J. Oncol. 31, 1223-1230.
33. Valdehita A., Bajo A.M., Fernández-Martínez A.B., Arenas M.I., Vacas E., Valenzuela P., Ruíz-Villaespesa A., Prieto J.C. and Carmena M.J. (2010). Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides 31, 2035-2045.